Here's what I think about the Statnome prolect. Three things Dnap has on their web site 1] "Latest scientific Breakthrough";2]DNAPrint Presents Statin Classifier At Chicago DMC Meeting Monday September 23, 11:05 am ET; and 3] what Tony said at the 2003 stockholders meeting. Tell's me that Tony has applyed for An application for market approval from the FDA back in Sept.2002 for Lipitor and Zocor.

By virtue of the agreement with Orchid, the Company has the freedom to seek other licensees with equivalent or better distribution channels on better terms than that which it could obtain from Orchid.

ltuccilnv, Your welcome and have a good night.

If Orchid does not match a competitive price, we are free to license to a third party.

On May 8, 2001, we entered into an employment agreement with Tony Frudakis, our Chief Science Officer and Secretary. The agreement runs for a term that commenced August 22, 2001 and expeires August 22, 2005, subject to extension from year to year by mutual agreement. The agreement initially provided a base salary of $95,000 per year to Dr. Frudakis. We increased this salary to $130,000 per year in 2001, and our Board of Directors may increase the salary from time to time in its discretion. The employment agreement also permits the Board of
Directors to authorize payment of discretionary bonuses or other benefits to Dr.
Frudakis.

As of April 11, 2003, there were 804 owners of record of our common stock.

Competition

Compared to fields such as telecom or wireless, there is little significant competition within the pharmacogenomics field. Only a handful of companies in the world have high-throughput genotyping capabilities (25,000 genotypes per day
or greater). In addition, data analysis represents a significant barrier to entering the field for many of these companies. In part, this is because doctoral level mathematicians and geneticists are necessary to build the
information tools necessary to conduct this type of research. Because of the esoteric nature of the field, high cost of equipment and intellectual property, and limited personnel, there are only a handful of companies in the world that
perform pharmacogenomics research and development. Most of these companies practice SNP profiling to accelerate gene discovery and product evaluation for pharmaceutical partners (i.e. studying experimental drugs). In contrast, we
focus on drugs with existing markets, and existing consumer genomics markets.

We are aware of only a few other companies whose goals resemble ours. About ten pharmaceutical companies are engaged in the pharmacogenomic field. Few are devoted to complex trait determination through SNP profiling; most are focused
on single gene disorders and phenotypes.

Some of the more sophisticated players in the pharmaceutical industry include Curagen (which has had success with Type II diabetes), Millennium (which has had success with arteriosclerosis and heart disease), and Warner-Lambert,
GenSet, Parke Davis and Glaxo Wellcome, which have had success with various drug interactivity traits. There are over 1,000 drugs with adverse events or variable efficacy in the Physicians Desk Reference. Since a pharmacogenomics drug study
costs millions of dollars, and since most of the handful of companies with expertise in this field are focused on experimental drugs (not drugs already on the market and present in the Physicians Desk Reference), the Company believes
that the competition landscape is favorable.

There has been discussion and commentary regarding the possibility that the FDA will eventually mandate the use of validated chemo-predictive tests. DNAPrint is among a handful of companies attempting to develop such tests. If successful,
the Company believes its market could grow exponentially if the tests are eventually mandated by the FDA.

Within the pharmacogenomics market, the Company has already developed and expects to soon market a chemo-predictive test, OVANOME, for the drug Taxol, one of the most commonly used chemotherapeutic agents for cancer. OVANOME is a
genomic-based diagnostic tool used to predict the likelihood of response of ovarian cancer patients to therapy with Taxol. We expect to complete clinical trials of this product in 2004, but various factors including profitability from forensics testing and the procurement of investment could accelerate this
schedule. An application for market approval, if required, will be submitted to the FDA later in 2004, and DNAPrint believes final approval could be received as early as the first quarter of 2005. We are in the latter stages of negotiation
with a pharmaceutical company interested in the OVANOME test, though the Company may choose to market the test on its own to maximize shareholder benefit. The Company's test would give one generic manufacturer a competitive advantage over another in the eyes of payors. DNAPrint expects this will be a trend that
defines the market for chemo predictive tests until the dominant pharmaceutical companies embrace them as integral to their business of not merely developing, but marketing new drugs.

eb0783,the info. is from the 10ksb Dec,2002 and most likely in the others.

SNiPdoc" SNP discovery system. The Company maintains a full, high volume screening facility, and the SNIPdoc system is the discovery search engine for this facility. SNIPdoc is a software system that aligns raw DNA sequence data from multiple donors, and uses statistical routines to find reliable discrepancies between these sequences. It then formats the data and deposits it into a database.

SNiPdoc" SNP discovery system. The Company maintains a full, high volume screening facility, and the SNIPdoc system is the discovery search engine for this facility. SNIPdoc is a software system that aligns raw DNA sequence data from multiple donors, and uses statistical routines to find reliable discrepancies between these sequences. It then formats the data and deposits it into a database.

The Company has developed unique and comprehensive
SNP databases. A "SNP" is a single nucleotide polymorphism -- a common DNA sequence variation that has great significance for biomedical research. DNAPrint has developed its own SNP databases through the use of proprietary data mining techniques, software and biochemical research and development. To date, DNAP scientists have discovered
several thousand SNP sequences useful for drug interactivity
screening. DNAP's databases are fully annotated, and contain relevant LocusLink, Medline, UniGene, Entrez, and PubMed information. Another factor that distinguishes DNAP's database is that it contains a molecular address for each target SNP that enables rapid application to microchip based screening platforms. Most of the Company's data and annotation do not currently exist in any public database, and the
Company enjoys their exclusive use.

Worktoplay, thanks, got a bad cold this weekend and need a little help.

Anyone remember Myung Ho Kim, Ph.D. Mathematics at Dnap and what happen to him????
Director of Informatics and Lead Mathemetician. Myung recieved his Ph.D. =in Mathematics from the University of Michigan in Ann Arbor in 1988 and M=.S. in Mathematics from The Ohio State University in Columbus Ohio. Most =recently, Myung worked on the Ant World Server project supported by DARPA=
(Defense Advanced Research Progect Agency) and implemented Kolmogorov-Sm=irnov tests, linear/nonlinear regression, nonparametric analysis and mode=ling to a TREC 6 (Text Retrieval Conference) project using SAS, C/C++ and=
Perl languages. Prior to this, Myung simulated mathematical modeling for=breast tumors and implemented/developed various image processing algorit=hms. He has served as an Honorary research Fellow in the Department of Ma=thematics and Information Science at the University of Auckland, New Zeal=
and and a Visiting Research Scholor in the Department of Mathematics at t=he University of California at Santa Cruz in California. Prior to coming =to the United States, Myung held the position of Assistant Professor in t=he Department of Mathematics at Sungkyunkwan University in Soel Korea.=20

I see stockholder101 is puting his 2 cents worth in today on the rb board. I glad I'm not posting over there anymore.

eb0783,ok thanks,was just looking for clarity on worktoplays post, I think I got a fair understanding of "A change of control" but i really wanted a good understanding of it.

Some info. on "A chande in Control" - http://www.occ.treas.gov/corpbook/forms/fg3b0301.pdf

worktoplay #10 says list any offer to shareholders,what your take on this.

Worktoplay,is this the form they would use and if so who's coming and who's going ? http://www.fdic.gov/regulations/laws/forms/interag2.pdf

bignbullish

I think it can be interpeted as a need for cash if pending news is big enough. Tony would have to get things in place in a hurry, and for really big news there is a lot of things that need to be upgraded. But having said that One must also consider that the money coming into dnap for the 2qt. should show profit.I dont think it is important from which direction the money comes as is where it is going.I think the money will be in porportion to the need.Tony will spend it wisely.This comp. is growing and in every stage need to upgrade.

bignbullish

my understanding of the form 144 is finite and I know there are others here who can better shead some light on this. But I believe the form is for the buying and or selling of shares. In this case it is for the selling of shares.The 4 million put up for sale is only around 8 % of Tony's listed holdings a very small amount. And because of this it makes me think that a nice little profit is soon to come his way by the selling of the shares.To me it is a "SAFE" way around the sec. rules on the issue of disclosure and Tony is leting us know by it that something big is at hand. Thats my take on it. Hope it makes sence.

VENKATESWARLU, KUNDRAGUNTA filed 144 in june and he has never done this. And Tony in July files 144. Two comp. officers a mo. apart.Something BIG BIG BIG Coming.

Here are some of Dnap's products;
Forensics DNA Classifiers:
Retinome {sm}- shade of eye color
Retinome {tm}- Genetic eye color classifier
Retinome {tm-ha} Hair color classifier
DNAWitness suit classifier
Height and weight classifier in pending status

Ancestrybydna 2.0 classifier - for continental affiliation

Ancestrybydna 3.0 classifier - for ethnic affiliation

Statnome classifier - info. can be found on their web and newsletter.

Ovarian Classifier - info. can be found on their web and their newsletter.

ADMIXMAP - A whole new Genome Screening Platform that is combined w/ other compositions and NEW highly Specialized Analytical Alogorithms.

University of Miami/ Jackson Memorial Medical center - Breast Cancer project due to end by 2003.

NYS Mary Lee Johnson Richards Organ Transplantation center - project to come to its end 2003.

And so much more !!!!

Good morning everyone just got up and read some of the posts, Thanks to all. The dates i posted were taken from Dnap's web site in investor info. slot under press releases.So if it fell on the weekend i didn;t know, just looked at the numbers. I think it would be great to see Dnap hit $4.00 for nasdaq. So thanks again cosmiclifeform and 2yrs2retire and everyone else got to go to work, later.

commando, Thanks, not to long now and we will all get togeather for a party.

ustacud, Here's hopen with you kid.LOL I do believe in Dnap and think Tony and comp. will reach their goals and we will all do well. Thanks and God Bless

commando, I'm here to just have a little fun, share in some info. and Hope, commando. I support a family of 4 my chrilden have to share a room that is full to the brim with toys they got over the years. I live in a small 2 bed room apt. with no backyard for them to play in.Some times i cant afford to take them to the park so we go for walks instead. I have to ride a bike to work and I could go on but the point i'm trying to make is i'm am not in a position to pump and day trade anything. I've got holes in my socks. LOL its true believe me. I've been looking at this comp. for over 3 years and I took a chance and spent what i had to buy 700,000 shares now I wait, I wait for my chrilden my wife and other family members who are also not doing so well. I wait and hope that some day I will have a house with a backyard for my chrilden and a nice car. But for now I wait. and try to have a little fun till something happens. The bills keep coming and coming but i hold and wait. because i have faith, Hope and I try not to worrie.I hope this helps you understand my position here with Dnap. It is by far the very best comp. i have seen and hope to god it helps my family. Now i think i used up 12 or 13 posts today not many left. Lighten up Bro. I'm on your side.

commando, I have no idea what the h.e.l.l your talking about. I'm just trying to have a little LIGHT fun. relax will ya.

Here's the chart on press releases:
DAY_____# of pr's that fell on that day

19______2

20------4

21------1

22------2

23------2

24------2

25------3

26------1

27------3

28------1

29------2

30-----3

31-------0

RETRO, what do you want from me your getting free pizza and beer if i wrong, now you want more, man. LOL

OK ! still not good enough. Free Pizza everything on it and free Beer OK - BUT, BUT, BUT If i'm right press release on the 20th than what do i get and it better be big.

So you think i'm cheap !!! OK Free pizza with everything on it, OK.

What ? You dont like Pizza ? WOW !!!

ok come on give me a break I changed my mine. {hay i'm buying the pizza} Press Release on the 20th or free Pizza for everyone.

chart says the 20th !!!

Ok my chart says thethe 20th Press release coming but I picked the 19th. Ok if your smart you will pick the 20th.

Ok i'm going way out on the lim onthis one so i'll BET, FREE Pizza on the house for everyone, if I'm wrong - Big Pr on the 19th.Anyone want to top that bet ?

HERE comes the 19th !!!! Could we have the BIG one on the 19th. Looking very strong here. The 19th, the 19th what could it hold ? We will see !!!!!!!!!!!!!$$$$$$$$$$$$$$

Niklinna, Aug 9,2002 press release

Almost a dz. press releases